Skip to main content
. 2021 Sep 1;14:4671–4692. doi: 10.2147/OTT.S313669

Table 5.

Potential Barriers to Biomarker Testing

Access to targeted therapies118,135,137–139,143
Reimbursement for testing133,138
Tissue sample quality98,143
TAT for test results42,120,131
Coordination among multiple specialist groups126
Accurate interpretation of results/physician education118

Abbreviation: TAT, turnaround time.